A Proof of Concept Study to Evaluate the Peak Bronchoprotection Conferred by Single and Chronic Dosing With Levosalbutamol and Racemic Salbutamol in Persistent Asthmatics. (NAI007)

NCT00830882 Phase 4 WITHDRAWN

The objective of this study is to compare the peak dose relative bronchoprotection offered by levosalbutamol and racemic salbutamol in mild to moderate asthmatics preselected into two groups on the basis of their beta-2 adrenoreceptor polymorphisms.

Details

Lead sponsor	University of Dundee
Phase	Phase 4
Status	WITHDRAWN
Start date	2009-01
Completion	2010-01

Conditions

• Asthma

Interventions

• levosalbutamol
• racemic salbutamol
• placebo

Primary outcomes

• Methacholine challenge — Before and 30 mins after drug administration, and after 2 weeks of chronic treatment

Countries

United Kingdom